Perspective of using in vitro models to understand immunotherapy-induced cytokine release syndrome
Since the TGN1412 clinical trial failure to predict cytokine release syndrome (CRS) during preclinical trials, alternative in vitro models have become increasingly important for identifying potential adverse outcomes in early drug development. Consider…